FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2294866259> ?p ?o ?g. }

• W2294866259 endingPage "1130" @default.
• W2294866259 startingPage "1124" @default.
• W2294866259 abstract "PURPOSE A phase II trial that used a regimen of interleukin-2 (IL-2) and interferon alfa-2a (IFN-alpha) was undertaken to evaluate the efficacy of this combination in the treatment of metastatic renal cell carcinoma. PATIENTS AND METHODS Thirty-four assessable patients were treated with one to two induction cycles of IL-2 administered by continuous intravenous (IV) infusion at a dose of 3 x 10(6) U/m2/d [corrected] for 4 days per week plus IFN-alpha administered by subcutaneous injection at a dose of 5 x 10(6) U/m2/d [corrected] for 4 days per week for 3 consecutive weeks. A maintenance regimen of IL-2 2 x 10(6) U/m2/d [corrected] given by continuous IV infusion for 5 days per week plus IFN-alpha subcutaneously at a dose of 6 x 10(6) U/m2/d [corrected] that was given 3 days per week for 3 weeks was administered for one to five cycles. Twenty-eight patients (82%) completed one to two induction cycles, and 14 patients (41%) received maintenance doses. RESULTS Major responses were achieved in four patients (12%), which included one complete response (CR) in a bone metastasis. Responses were observed in patients both with and without prior nephrectomy as well as in a primary tumor. Toxicity was moderately severe and included two treatment-related deaths. CONCLUSIONS In view of the minimal antitumor activity and associated toxicity, the combination of IL-2 and IFN-alpha in this trial cannot be recommended. The investigation of new cytokines and the identification of biologic prognostic factors for a response to immunologic therapy are essential." @default.
• W2294866259 created "2016-06-24" @default.
• W2294866259 creator A5028538472 @default.
• W2294866259 creator A5035865205 @default.
• W2294866259 creator A5040854836 @default.
• W2294866259 creator A5059063118 @default.
• W2294866259 creator A5059219836 @default.
• W2294866259 creator A5062419531 @default.
• W2294866259 creator A5064884168 @default.
• W2294866259 creator A5070062710 @default.
• W2294866259 creator A5072850546 @default.
• W2294866259 creator A5087658026 @default.
• W2294866259 date "1992-07-01" @default.
• W2294866259 modified "2023-10-17" @default.
• W2294866259 title "A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma." @default.
• W2294866259 cites W153538655 @default.
• W2294866259 cites W1567654782 @default.
• W2294866259 cites W1862901090 @default.
• W2294866259 cites W1913909511 @default.
• W2294866259 cites W1949673766 @default.
• W2294866259 cites W1985981664 @default.
• W2294866259 cites W1988620632 @default.
• W2294866259 cites W2022101147 @default.
• W2294866259 cites W2027581129 @default.
• W2294866259 cites W2036275492 @default.
• W2294866259 cites W2042579365 @default.
• W2294866259 cites W2046472791 @default.
• W2294866259 cites W2047786043 @default.
• W2294866259 cites W2053414650 @default.
• W2294866259 cites W2057894414 @default.
• W2294866259 cites W2065959851 @default.
• W2294866259 cites W2101371955 @default.
• W2294866259 cites W2108162873 @default.
• W2294866259 cites W2132779751 @default.
• W2294866259 cites W2133988080 @default.
• W2294866259 cites W2138463196 @default.
• W2294866259 cites W2149724818 @default.
• W2294866259 cites W2164006518 @default.
• W2294866259 cites W2242340339 @default.
• W2294866259 cites W2261057536 @default.
• W2294866259 cites W2285002277 @default.
• W2294866259 cites W2322553446 @default.
• W2294866259 cites W2326245275 @default.
• W2294866259 cites W2395220548 @default.
• W2294866259 cites W2400597124 @default.
• W2294866259 cites W2411109909 @default.
• W2294866259 cites W2415529413 @default.
• W2294866259 doi "https://doi.org/10.1200/jco.1992.10.7.1124" @default.
• W2294866259 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1607918" @default.
• W2294866259 hasPublicationYear "1992" @default.
• W2294866259 type Work @default.
• W2294866259 sameAs 2294866259 @default.
• W2294866259 citedByCount "63" @default.
• W2294866259 countsByYear W22948662592014 @default.
• W2294866259 countsByYear W22948662592020 @default.
• W2294866259 countsByYear W22948662592022 @default.
• W2294866259 countsByYear W22948662592023 @default.
• W2294866259 crossrefType "journal-article" @default.
• W2294866259 hasAuthorship W2294866259A5028538472 @default.
• W2294866259 hasAuthorship W2294866259A5035865205 @default.
• W2294866259 hasAuthorship W2294866259A5040854836 @default.
• W2294866259 hasAuthorship W2294866259A5059063118 @default.
• W2294866259 hasAuthorship W2294866259A5059219836 @default.
• W2294866259 hasAuthorship W2294866259A5062419531 @default.
• W2294866259 hasAuthorship W2294866259A5064884168 @default.
• W2294866259 hasAuthorship W2294866259A5070062710 @default.
• W2294866259 hasAuthorship W2294866259A5072850546 @default.
• W2294866259 hasAuthorship W2294866259A5087658026 @default.
• W2294866259 hasConcept C126322002 @default.
• W2294866259 hasConcept C126894567 @default.
• W2294866259 hasConcept C141071460 @default.
• W2294866259 hasConcept C203014093 @default.
• W2294866259 hasConcept C2776178377 @default.
• W2294866259 hasConcept C2777472916 @default.
• W2294866259 hasConcept C2780091579 @default.
• W2294866259 hasConcept C2780227381 @default.
• W2294866259 hasConcept C2781228144 @default.
• W2294866259 hasConcept C2781413609 @default.
• W2294866259 hasConcept C2909179924 @default.
• W2294866259 hasConcept C29730261 @default.
• W2294866259 hasConcept C71924100 @default.
• W2294866259 hasConcept C90924648 @default.
• W2294866259 hasConceptScore W2294866259C126322002 @default.
• W2294866259 hasConceptScore W2294866259C126894567 @default.
• W2294866259 hasConceptScore W2294866259C141071460 @default.
• W2294866259 hasConceptScore W2294866259C203014093 @default.
• W2294866259 hasConceptScore W2294866259C2776178377 @default.
• W2294866259 hasConceptScore W2294866259C2777472916 @default.
• W2294866259 hasConceptScore W2294866259C2780091579 @default.
• W2294866259 hasConceptScore W2294866259C2780227381 @default.
• W2294866259 hasConceptScore W2294866259C2781228144 @default.
• W2294866259 hasConceptScore W2294866259C2781413609 @default.
• W2294866259 hasConceptScore W2294866259C2909179924 @default.
• W2294866259 hasConceptScore W2294866259C29730261 @default.
• W2294866259 hasConceptScore W2294866259C71924100 @default.
• W2294866259 hasConceptScore W2294866259C90924648 @default.
• W2294866259 hasIssue "7" @default.
• W2294866259 hasLocation W22948662591 @default.

• next